Medical ozone alleviates acute lung injury by enhancing phagocytosis targeting NETs via AMPK/SR-A1 axis

Abstract

Acute lung injury (ALI) linked to sepsis has a high mortality rate, with limited treatment options available. In recent studies, medical ozone has shown the potential to alleviate inflammation and infection. Here, we aimed to evaluate therapeutic potential of medical ozone in a mouse model of the sepsis-induced ALI by measuring behavioral assessments, lung function, and blood flow. Protein levels were quantified by Western blotting. In vitro, we performed experiments on bone marrow-derived macrophages (BMDMs) to investigate the effect of adenosine monophosphate (AMP)-activated protein kinase (AMPK) inhibitors and agonists on their phagocytic activity. The results showed that medical ozone significantly improved the survival rate, ameliorated lung injury, and enhanced lung function and limb microcirculation in mice with ALI. Notably, medical ozone inhibited the formation of neutrophil extracellular traps (NETs), a crucial factor in the ALI development. Additionally, medical ozone counteracted the elevated levels of tissue factor, matrix metalloproteinase-9, and interleukin-1β. In the ALI mice, the effects of ozone were abolished, and BMDMs showed an impaired capacity to engulf NETs following the Sr-a1 knockout. Under normal physiological conditions, the administration of an AMPK antagonist showed similar effects on the Sr-a1 knockout, significantly inhibiting the phagocytosis of NETs by BMDMs. In contrast, AMPK agonists enhanced this phagocytic process. In conclusion, medical ozone may alleviate the sepsis-induced lung injury through the AMPK/SR-A1 pathway, thereby enhancing the phagocytosis of NETs by macrophages.

Keywords

SR-A1 / NETs / ALI / phagocytosis / ozone therapy

Fundings

This work was supported by the National Natural Science Foundation of China (Grant Nos. 82271252, 82204542, and 81971047), the Lianyungang Science and Technology Program Project (Grant Nos. SF2122 and SF2214), the Scientific Research Project of Jiangsu Provincial Health Commission (Grant No. Z2021066), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (Grant No. 21KJB310019), and the Open Project of Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University (Grant No. XZSYSKF2021014).

Acknowledgments

The authors would like to thank Professor Qi Chen for kindly providing the knockout mice.

References

[1] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. doi: 10.1001/jama.2016.0287

[2] Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units[J]. JAMA, 2009, 302(21): 2323-2329. doi: 10.1001/jama.2009.1754

[3] Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study[J]. Crit Care Med, 2006, 34(2): 344-353. doi: 10.1097/01.CCM.0000194725.48928.3A

[4] Chen C, He Y, Feng Y, et al. Long non-coding RNA review and implications in acute lung inflammation[J]. Life Sci, 2021, 269: 119044. doi: 10.1016/j.lfs.2021.119044

[5] Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome[J]. Nat Rev Dis Primers, 2019, 5(1): 18. doi: 10.1038/s41572-019-0069-0

[6] Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment[J]. JAMA, 2018, 319(7): 698-710. doi: 10.1001/jama.2017.21907

[7] Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock[J]. Lancet, 2018, 392(10141): 75-87. doi: 10.1016/S0140-6736(18)30696-2

[8] Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury[J]. Mol Med, 2011, 17(3-4): 293-307. doi: 10.2119/molmed.2010.00138

[9] Chen C, Zhang Z, Tan F, et al. Stabilizing mast cells improves acute lung injury after orthotopic liver transplantation via promotion of apoptosis in polymorphonuclear neutrophils[J]. Am J Physiol Lung Cell Mol Physiol, 2021, 320(2): L266-L275. doi: 10.1152/ajplung.00046.2020

[10] Papayannopoulos V. Neutrophil extracellular traps in immunity and disease[J]. Nat Rev Immunol, 2018, 18(2): 134-147. doi: 10.1038/nri.2017.105

[11] Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria[J]. Science, 2004, 303(5663): 1532-1535. doi: 10.1126/science.1092385

[12] Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in noninfectious disease[J]. Nat Med, 2017, 23(3): 279-287. doi: 10.1038/nm.4294

[13] Lee KH, Kronbichler A, Park DDY, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review[J]. Autoimmun Rev, 2017, 16(11): 1160-1173. doi: 10.1016/j.autrev.2017.09.012

[14] Zhang H, Zhou Y, Qu M, et al. Tissue factor-enriched neutrophil extracellular traps promote immunothrombosis and disease progression in sepsis-induced lung injury[J]. Front Cell Infect Microbiol, 2021, 11: 677902. doi: 10.3389/fcimb.2021.677902

[15] MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome[J]. Pharmacotherapy, 2007, 27(6): 860-873. doi: 10.1592/phco.27.6.860

[16] Alsabani M, Abrams ST, Cheng Z, et al. Reduction of NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in experimental human and murine sepsis[J]. Br J Anaesth, 2022, 128(2): 283-293. doi: 10.1016/j.bja.2021.10.039

[17] Taban Q, Mumtaz PT, Masoodi KZ, et al. Scavenger receptors in host defense: from functional aspects to mode of action[J]. Cell Commun Signal, 2022, 20(1): 2. doi: 10.1186/s12964-021-00812-0

[18] Alquraini A, El Khoury J. Scavenger receptors[J]. Curr Biol, 2020, 30(14): R790-R795. doi: 10.1016/j.cub.2020.05.051

[19] Zani IA, Stephen SL, Mughal NA, et al. Scavenger receptor structure and function in health and disease[J]. Cells, 2015, 4(2): 178-201. doi: 10.3390/cells4020178

[20] Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity[J]. Curr Opin Immunol, 2002, 14(1): 123-128. doi: 10.1016/S0952-7915(01)00307-7

[21] Peiser L, Gordon S. The function of scavenger receptorsexpressed by macrophages and their rolein the regulation of inflammation[J]. Microbes Infect, 2001, 3(2): 149-159. doi: 10.1016/S1286-4579(00)01362-9

[22] Yu H, Ha T, Liu L, et al. Scavenger receptor A (SR-A) is required for LPS-induced TLR4 mediated NF-κB activation in macrophages[J]. Biochim Biophys Acta (BBA)-Mol Cell Res, 2012, 1823(7): 1192-1198. doi: 10.1016/j.bbamcr.2012.05.004

[23] Ben J, Zhu X, Zhang H, et al. Class A1 scavenger receptors in cardiovascular diseases[J]. Br J Pharmacol, 2015, 172(23): 5523-5530. doi: 10.1111/bph.13105

[24] Haider P, Kral-Pointner JB, Mayer J, et al. Neutrophil extracellular trap degradation by differently polarized macrophage subsets[J]. Arterioscler Thromb Vasc Biol, 2020, 40(9): 2265-2278. doi: 10.1161/ATVBAHA.120.314883

[25] Grégoire M, Uhel F, Lesouhaitier M, et al. Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS[J]. Eur Respir J, 2018, 52(2): 1702590. doi: 10.1183/13993003.02590-2017

[26] Hernández Rosales FA, Calunga Fernández JL, Turrent Figueras J, et al. Ozone therapy effects on biomarkers and lung function in asthma[J]. Arch Med Res, 2005, 36(5): 549-554. doi: 10.1016/j.arcmed.2005.04.021

[27] Bocci V, Zanardia I, Valacchi G, et al. Validity of oxygen-ozone therapy as integrated medication form in chronic inflammatory diseases[J]. Cardiovasc Hematol Disord Drug Targets, 2015, 15(2): 127-138. doi: 10.2174/1871529X1502151209114642

[28] Migliorini F, Maffulli N, Eschweiler J, et al. Ozone injection therapy for intervertebral disc herniation[J]. Br Med Bull, 2020, 136(1): 88-106. doi: 10.1093/bmb/ldaa032

[29] Sconza C, Respizzi S, Virelli L, et al. Oxygen-ozone therapy for the treatment of knee osteoarthritis: a systematic review of randomized controlled trials[J]. Arthroscopy, 2020, 36(1): 277-286. doi: 10.1016/j.arthro.2019.05.043

[30] Yu Q, Yang X, Zhang C, et al. AMPK activation by ozone therapy inhibits tissue factor-triggered intestinal ischemia and ameliorates chemotherapeutic enteritis[J]. FASEB J, 2020, 34(9): 13005-13021. doi: 10.1096/fj.201902717RR

[31] Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis[J]. Crit Care, 2013, 17(6): R297. doi: 10.1186/cc13163

[32] Gando S, Saitoh D, Ogura H, et al. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis[J]. Crit Care, 2013, 17(3): R111. doi: 10.1186/cc12783

[33] Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation[J]. Anesthesiology, 2020, 132(5): 1238-1245. doi: 10.1097/ALN.0000000000003122

[34] Li P, Li M, Lindberg MR, et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps[J]. J Exp Med, 2010, 207(9): 1853-1862. doi: 10.1084/jem.20100239

[35] Wujak L, Schnieder J, Schaefer L, et al. LRP1: a chameleon receptor of lung inflammation and repair[J]. Matrix Biol, 2018, 68-69: 366-381.

[36] Zaky S, Kamel SE, Hassan MS, et al. Preliminary results of ozone therapy as a possible treatment for patients with chronic hepatitis C[J]. J Altern Complement Med, 2011, 17(3): 259-263. doi: 10.1089/acm.2010.0016

[37] Cattel F, Giordano S, Bertiond C, et al. Ozone therapy in COVID-19: a narrative review[J]. Virus Res, 2021, 291: 198207. doi: 10.1016/j.virusres.2020.198207

[38] Braidy N, Izadi M, Sureda A, et al. Therapeutic relevance of ozone therapy in degenerative diseases: Focus on diabetes and spinal pain[J]. J Cell Physiol, 2018, 233(4): 2705-2714. doi: 10.1002/jcp.26044

[39] Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management[J]. BMJ, 2016, 353: i1585. doi: 10.1136/bmj.i1585

[40] Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis[J]. N Engl J Med, 2003, 348(2): 138-150. doi: 10.1056/NEJMra021333

[41] Park I, Kim M, Choe K, et al. Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury[J]. Eur Respir J, 2019, 53(3): 1800786. doi: 10.1183/13993003.00786-2018

[42] Vincent JL, Zhang H, Szabo C, et al. Effects of nitric oxide in septic shock[J]. Am J Respir Crit Care Med, 2000, 161(6): 1781-1785. doi: 10.1164/ajrccm.161.6.9812004

[43] Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock[J]. N Engl J Med, 2001, 345(19): 1368-1377. doi: 10.1056/NEJMoa010307

[44] Bezemer R, Bartels SA, Bakker J, et al. Clinical review: Clinical imaging of the sublingual microcirculation in the critically ill-where do we stand?[J]. Crit Care, 2012, 16(3): 224. doi: 10.1186/cc11236

[45] Steinberg BE, Grinstein S. Unconventional roles of the NADPH oxidase: Signaling, ion homeostasis, and cell death[J]. Sci STKE, 2007, 2007(379): pe11. doi: 10.1126/stke.3792007pe11

[46] Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus[J]. Sci Transl Med, 2011, 3(73): 73ra19. doi: 10.1126/scitranslmed.3001180

[47] Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis[J]. Sci Transl Med, 2013, 5(178): 178ra40. doi: 10.1126/scitranslmed.3005580

[48] Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis[J]. Am J Pathol, 2011, 179(1): 199-210. doi: 10.1016/j.ajpath.2011.03.013

[49] Wang Y, Li M, Stadler S, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation[J]. J Cell Biol, 2009, 184(2): 205-213. doi: 10.1083/jcb.200806072

[50] Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome[J]. Am J Med, 1976, 61(5): 585-589. doi: 10.1016/0002-9343(76)90135-2

[51] Middleton EA, He X, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome[J]. Blood, 2020, 136(10): 1169-1179. doi: 10.1182/blood.2020007008

[52] Stakos D, Skendros P, Konstantinides S, et al. Traps N' clots: NET-mediated thrombosis and related diseases[J]. Thromb Haemost, 2020, 120(3): 373-383. doi: 10.1055/s-0039-3402731

[53] Chen D, Giannopoulos K, Shiels PG, et al. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium[J]. Blood, 2004, 104(5): 1344-1349. doi: 10.1182/blood-2003-12-4365

[54] Owens III AP, Mackman N. Tissue factor and thrombosis: the clot starts here[J]. Thromb Haemost, 2010, 104(3): 432-439. doi: 10.1160/TH09-11-0771

[55] Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis[J]. Arterioscler Thromb Vasc Biol, 2018, 38(4): 709-725. doi: 10.1161/ATVBAHA.117.309846

[56] Kim JH, Suk MH, Yoon DW, et al. Inhibition of matrix metalloproteinase-9 prevents neutrophilic inflammation in ventilator-induced lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2006, 291(4): L580-L587. doi: 10.1152/ajplung.00270.2005

[57] Belaaouaj AA, Li A, Wun TC, et al. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation[J]. J Biol Chem, 2000, 275(35): 27123-27128. doi: 10.1074/jbc.M004218200

[58] Schagat TL, Wofford JA, Wright JR. Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils[J]. J Immunol, 2001, 166(4): 2727-2733. doi: 10.4049/jimmunol.166.4.2727

[59] Poller W, Willnow TE, Hilpert J, et al. Differential recognition of α₁-antitrypsin-elastase and α₁-antichymotrypsin-cathepsin G complexes by the low density lipoprotein receptor-related protein[J]. J Biol Chem, 1995, 270(6): 2841-2845. doi: 10.1074/jbc.270.6.2841

[60] Yang X, Jia R, Hu F, et al. Promoting AMPK/SR-A1-mediated clearance of HMGB1 attenuates chemotherapy-induced peripheral neuropathy[J]. Cell Commun Signal, 2023, 21(1): 99. doi: 10.1186/s12964-023-01100-9

[61] Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases[J]. Lancet, 2022, 400(10354): 769-786. doi: 10.1016/S0140-6736(22)01052-2

[62] Zhang S, Shu X, Tian X, et al. Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications[J]. Clin Exp Immunol, 2014, 177(1): 134-141. doi: 10.1111/cei.12319

[63] Peng Y, Zhang S, Zhao Y, et al. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis[J]. Clin Rheumatol, 2018, 37(1): 107-115. doi: 10.1007/s10067-017-3799-y

[64] Chrysanthopoulou A, Mitroulis I, Apostolidou E, et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts[J]. J Pathol, 2014, 233(3): 294-307. doi: 10.1002/path.4359

[65] Takemasa A, Ishii Y, Fukuda T. A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice[J]. Eur Respir J, 2012, 40(6): 1475-1482. doi: 10.1183/09031936.00127011

[66] Suzuki M, Ikari J, Anazawa R, et al. PAD4 deficiency improves bleomycin-induced neutrophil extracellular traps and fibrosis in mouse lung[J]. Am J Respir Cell Mol Biol, 2020, 63(6): 806-818. doi: 10.1165/rcmb.2019-0433OC

[67] Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress?[J]. Med Gas Res, 2011, 1: 29. doi: 10.1186/2045-9912-1-29

[68] Smith NL, Wilson AL, Gandhi J, et al. Ozone therapy: An overview of pharmacodynamics, current research, and clinical utility[J]. Med Gas Res, 2017, 7(3): 212-219. doi: 10.4103/2045-9912.215752